GENSCRIPT BIO announced that, under the collaboration and license agreement signed on December 21, 2017, between Legend Biotech Corporation (an associate of the company whose shares are listed on the NASDAQ Global Select Market in the form of American Depositary Shares) and Janssen Biotech, Inc., CARVYKTI® generated approximately $597 million in net trade sales for the quarter ended March 31, 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments